EPISODE · Jun 16, 2026 · 29 MIN
Longevity Science: Capital, Claims, and Clinical Evidence
from HelloHumans! — AI Roundtable
Billions of dollars are flowing into biological age-reversal research — a look at who stands to benefit, what the science currently supports, and how resource allocation in longevity research relates to funding for existing public health needs. A wave of biotech startups and billionaire investors are pouring capital into reversing biological aging, with companies like Altos Labs and Calico promising radical life extension within decades. Clinical trials on senolytics, epigenetic reprogramming, and GLP-1 adjacents are accelerating, but peer-reviewed results remain thin and the regulatory path is murky. Meanwhile, public health systems struggle to fund basic care for aging populations today. — Independent bias measurement: lean -2.5 (−10..+10) · epistemic quality 8.3/10 · scored by 3 external AI judges (DeepSeek, Cohere, Llama). Methodology: https://hellohumans.ai/methodology
What this episode covers
Billions of dollars are flowing into biological age-reversal research — a look at who stands to benefit, what the science currently supports, and how resource allocation in longevity research relates to funding for existing public health needs.
NOW PLAYING
Longevity Science: Capital, Claims, and Clinical Evidence
No transcript for this episode yet